Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Shareholder vote
confidence 95%
filed 2026-09-01
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from a special meeting held on August 28, 2026. The filing reports voting outcomes on six material proposals including preferred stock issuances, convertible note and warrant authorizations, a stock plan amendment, and a reverse stock split authorization. All proposals passed with substantial majorities, and the dilutive issuances and reverse split authority are material to investors' assessment of capital structure and ownership dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-01
Item 1.01
The Amendment increases the total commitment under the ChEF Purchase Agreement from $1.0 billion to $2.5 billion for the issuance of newly issued common stock at prices below $12.02 per share, with an Exchange Cap of 19.99% of outstanding shares. This is a material unregistered equity issuance arrangement that would significantly dilute existing shareholders and is a key capital-raising mechanism for the company.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-09-01
Item 8.01
The filing discloses a quarterly cash dividend declaration of $1.65 per share payable on September 30, 2026, to holders of Class A and Class B common stock. This is a routine but material capital allocation decision that affects shareholder returns and is typical of dividend-paying companies. The press release explicitly announces the dividend declaration and payment details.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-09-01
Item 1.01
PMV Pharmaceuticals entered into an underwriting agreement on August 31, 2026 and priced a public offering of approximately $50.8 million in gross proceeds, consisting of 22,055,000 shares of common stock, 19,900,000 pre-funded warrants, and 41,955,000 common stock warrants. The company intends to use proceeds to fund late-stage clinical development and commercialization of rezatapopt.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-09-01
Item 3.03
NYSE American suspended trading of the Company's common stock on July 17, 2026, due to failure to meet the minimum trading price requirement of $0.10 and commenced delisting proceedings. Although the Company implemented a 1-for-40 reverse stock split to attempt compliance, there is no assurance that the delisting determination will be reversed, and failure to resume NYSE American trading would result in continued OTC trading with negative impacts on liquidity and financing ability.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 97%
filed 2026-09-01
Item 3.01
XTI Aerospace received a Nasdaq deficiency notice on August 26, 2026, for failure to timely file its Form 10-Q for Q2 2026, violating Nasdaq Listing Rule 5250(c)(1). The company has 60 days to submit a compliance plan or faces potential delisting, with no assurance it will regain or maintain compliance with Nasdaq's continued listing requirements.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-01
EX-99.2
Webuy entered into a non-binding Memorandum of Understanding with Moyu Travel to jointly develop China inbound travel experiences, expanding the company's operational capabilities and market reach in China through a local partnership. The announcement highlights strong growth metrics for WeTrip (9x YoY growth in Q2 2026), representing a material strategic development affecting the company's growth trajectory and competitive positioning in the China inbound travel market.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-01
EX-99.4
Webuy announced record preliminary unaudited travel bookings of US$4.76 million at the NATAS Fair in August 2026, representing a 42% increase from March 2026, with strong performance from the premium Altitude brand (21% of bookings), demonstrating significant operational momentum and customer demand across the company's multi-brand travel strategy.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-09-01
The 6-K discloses the entry into a share purchase agreement on August 27, 2026, by Millennium Strategic (an indirect wholly owned subsidiary) to sell all issued shares of Millennium Printing International Limited for HKD 14,800,000 (~USD 1.9M), subject to customary closing conditions. This constitutes a material disposition of a subsidiary. The transaction also involves a related-party debt assumption and set-off arrangement with Yee Cheong, whose ultimate beneficial shareholders overlap with the Company's majority shareholder, triggering related-party transaction disclosure requirements and audit committee review.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-01
Item 8.01
AEye announced a "multi-million-dollar commercial engagement" with Lunar Outpost for integration of its Apollo lidar onto the Pegasus Lunar Terrain Vehicle, marking entry into the space mobility market. This is a material commercial contract award that diversifies the company's revenue streams and represents a significant operational milestone, but it does not fit the specific categories of M&A activity, debt issuance, or other defined financial events. The disclosure centers on a new strategic business partnership and market expansion rather than a routine operational matter.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-01
The 6-K announces the appointment of Mr. Xiaohui Li as co-executive officer of Jianzhi Education Technology Group Company Limited, effective September 1, 2026. The disclosure provides his background, prior roles at Zhiyi Eastern Securities and Shenzhen Hongying Capital Management, and educational credentials. This is a clear executive appointment that would affect a reasonable investor's assessment of the company's leadership and governance.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-01
EX-99.1
This press release announces a material clinical development milestone: initiation of Phase IIa of Clearmind's Phase I/IIa clinical trial for CMND-100 in alcohol use disorder treatment, with six patients enrolled across two Israeli medical centers. The announcement emphasizes successful completion of Part A safety data and a positive Data and Safety Monitoring Board recommendation to advance to multiple-dose phases. For a clinical-stage biopharmaceutical company, progression to Phase IIa with patient enrollment represents a significant operational and strategic milestone that would affect a reasonable investor's assessment of the company's development pipeline and near-term prospects.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 94%
filed 2026-09-01
Item 1.01
Profusa completed an additional closing under a Securities Purchase Agreement on September 1, 2026, issuing a Senior Secured Convertible Promissory Note with a principal amount of $329,670.33 for $300,000 in cash. The note is secured by substantially all company assets, carries a one-year maturity, 7% interest rate, and includes conversion features.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 75%
filed 2026-09-01
EX-99.1
The exhibit announces full conversion and extinguishment of US$2.2 million in senior promissory notes issued in December 2025. While the notes were originally issued as debt obligations, this announcement discloses the material resolution of that debt through conversion into Class A ordinary shares. The conversion eliminates a significant debt obligation (US$2.2 million) without cash outlay, materially affecting the company's capital structure and balance sheet. This is classified as debt_issuance because the core financial event involves the creation and now resolution of a direct financial obligation (the promissory notes), though the resolution mechanism is equity conversion rather than cash repayment.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-09-01
The 6-K discloses completion of a shareholder-approved continuation of the Company from the Cayman Islands to the British Virgin Islands and a name change from "Hitek Global Inc." to "Biddance AI Systems, Inc." on August 24, 2026. This is a governance event involving a material change in the registrant's domicile and legal identity, approved at the 2026 Annual General Meeting and now consummated. While not a standard named governance type (exec appointment, departure, compensation, or shareholder vote results), it is clearly a material governance restructuring that would affect a reasonable investor's assessment of the registrant's jurisdiction and legal standing.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-09-01
The filing discloses termination of a proposed business combination between Lionheart Holdings (a SPAC) and KEO Energy. The parties "mutually decided not to renew" the exclusivity period under the non-binding letter of intent dated July 15, 2026. This represents a material change in the status of a previously announced M&A transaction that would affect investor expectations regarding the SPAC's path to a business combination.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-09-01
The 6-K discloses a name change from "Raytech Holding Limited" to "Atlas Trinity Tech Limited" and a ticker symbol change from "RAY" to "ATTT," effective September 10, 2026. This is a governance/corporate identity event that would affect investor identification and trading of the security, though it does not involve a change in control, M&A activity, or financial results. The disclosure is material because it affects how the registrant is identified and traded in the market.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-01
EX-99.1
This press release announces a strategic cooperation framework agreement between Youlife's subsidiary and Ji'an Industry-Education Integration Technology Co., Ltd. to develop a vocational education park with exclusive operating rights and robotics/technology integration. The agreement represents a material operational expansion of the company's school-enterprise cooperation model into a new geographic market (Jiangxi region) with exclusive rights and infrastructure support, but does not constitute a discrete M&A transaction, material contract award, or other specifically-named event type. The five-year term, exclusive operating rights, and strategic positioning in a digital economy industrial park would affect a reasonable investor's assessment of growth prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-01
EX-99
IGI announces the launch of Cipher, a specialty treaty reinsurance MGA focused on cyber risk, in which IGI owns a 60% interest through its subsidiary IGI Managing Agencies Holdings Ltd. This represents a material strategic business expansion into a new product line and market segment (cyber treaty reinsurance), led by an experienced specialist (Ari Chatterjee). The press release emphasizes this as "an important milestone in IGI's strategy to expand its specialty reinsurance capabilities" and "a significant and exciting development," indicating materiality to investors assessing the company's growth trajectory and diversification efforts. While not fitting the specific categories of M&A, debt issuance, or workforce reduction, this operational and strategic initiative to establish a new underwriting platform would affect a reasonable investor's assessment of IGI's business prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-01
EX-99.1
The press release announces issuance of two Letters of Award for MEP equipment supply and installation for Phase 1A of the Company's planned AGCC-JKT01 data center in Indonesia, with an aggregate reference amount between US$65–75 million. This represents a material operational and strategic milestone in the Company's AI computing infrastructure initiative, a newly designated co-primary business line launched in February 2026. While the Letters of Award are infrastructure procurement arrangements (not customer revenue contracts) and carry significant execution risks, the scale of capital commitment and strategic importance to the Company's business transformation make this material to a reasonable investor's assessment of the registrant's operational direction and capital deployment.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-09-01
Item 4.01
This Item 4.01 discloses the resignation of Montis CPA Limited as the Company's independent registered public accounting firm on August 27, 2026, and the appointment of HCL, PLLC as successor auditor on August 29, 2026. The resignation was triggered by a material disagreement over the accounting treatment of a US$1,050,000 loan to the CEO, which Montis would not accept as an equipment purchase. This is a classic auditor change event with a substantive underlying dispute over accounting principles.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-01
Item 1.01
The disclosure describes entry into a material managed-services agreement with AIcreatesAI for AI transformation, digital operations, and growth support at $180,000 annually. While Item 1.01 typically covers M&A activity, this is a strategic operational partnership and services contract rather than an acquisition, merger, or change of control. The agreement is material to investors as it signals a significant operational and strategic pivot toward AI-driven transformation and includes provisions for deferred payment and potential equity issuance, but does not fit the specific M&A taxonomy categories.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-09-01
EX-99.1
BW LPG announces the launch of approximately USD 300 million in senior unsecured convertible bonds due 2031, with proceeds intended to finance a newbuild program and general corporate purposes. This is a material creation of a direct financial obligation under Item 2.03 of the 8-K taxonomy. The convertible feature does not change the classification—the primary event is the issuance of debt securities, not equity dilution.
View raw filing on EDGAR →
6-K
Other material
confidence 65%
filed 2026-09-01
This 6-K discloses multiple material events on September 1, 2026: (1) a third closing of a convertible note offering ($750,000 principal, convertible into Class A Ordinary Shares), which is a debt issuance with dilutive conversion features; (2) entry into two non-binding letters of intent for related-party acquisitions (IP Acquisition and MC Venture Acquisition, each $1–3M and $1–2M respectively, to be settled in newly issued shares); and (3) board approval of a 2026 Equity Incentive Plan with reservation of 3.66M shares. The filing bundles debt issuance, proposed M&A activity, and equity compensation planning in a single report. While each component is material, the report as a whole does not fit cleanly into a single event type—it is a multi-event disclosure. The dominant events are the convertible debt issuance (debt_issuance) and the two proposed acquisitions (ma_activity), but the filing also includes equity-plan governance. Given the mix of financial, operational, and governance elements and the inability to isolate a single primary event, other_material is the most appropriate classification.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-01
The filing discloses receipt of a notice from Nasdaq on August 26, 2026, stating that Borealis Foods no longer complies with Nasdaq Listing Rule 5250(c)(1) due to failure to timely file its Q2-2026 Form 10-Q. While the notice has no immediate effect on listing, the company has until October 26, 2026 to submit a compliance plan and until February 16, 2027 to regain compliance, creating a material delisting risk under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-09-01
EX-99.1
CollPlant announces a one-for-ten reverse share split explicitly "being implemented as part of the Company's strategic plan to regain compliance with the Nasdaq minimum bid price requirement for continued listing." This is a direct response to delisting risk — the company is taking corrective action to avoid loss of listing status. While the reverse split itself is a capital structure event, the disclosure's material substance is the underlying delisting threat and the company's remedial measure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-09-01
Global Mofy AI Limited entered into securities purchase agreements on August 31, 2026, for a registered direct offering of 3,796,000 Class A ordinary shares at $0.538 per share, raising approximately $2.04 million in gross proceeds. The offering was self-underwritten and registered under Form F-3. This is a dilutive equity issuance that would materially affect a reasonable investor's assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-01
Item 7.01
Polaryx Therapeutics appointed Will Charlton, M.D., M.A.S. as Chief Medical Officer, effective September 1, 2026. Dr. Charlton brings extensive experience in rare disease and pediatric drug development and will lead the company's planned SOTERIA Phase 2 trial initiation in Q4 2026, making this a material appointment for a clinical-stage biotech company on the eve of a pivotal trial launch.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-01
EX-99.1
Kazia announced preclinical and translational data for paxalisib in MSS/pMMR colorectal cancer, demonstrating tumor burden reduction and enhanced immunotherapy response, with plans to advance into a Phase 2 clinical trial beginning Q1 2027.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-01
EX-99.2
Kazia announced a material expansion of its paxalisib clinical development program into HR+/HER2- breast cancer, supported by preclinical data, with protocol amendment to its ongoing TNBC trial to add a three-arm expansion with first patient enrollment expected by end of 2026.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-09-01
The 6-K discloses shareholder approval at the August 25, 2026 annual general meeting of a special resolution to adopt the Sixth Amended and Restated Memorandum and Articles of Association, which reflects creation of Series A Preferred Shares and revises the quorum requirement for general meetings from an unspecified prior threshold to one-third of voting power. This is a governance event involving charter/bylaw amendment and preferred share authorization approved by shareholders. While routine bylaw amendments are typically immaterial, the creation of a new class of preferred shares and material changes to voting quorum requirements would affect a reasonable investor's assessment of capital structure and voting rights.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 97%
filed 2026-09-01
Item 3.01
CID HoldCo received a third delisting notice from Nasdaq on August 27, 2026, citing failure to file its Form 10-Q for the period ended June 30, 2026, in addition to prior determinations for failure to meet minimum market value requirements. The company's common stock remains listed pending a Nasdaq Hearings Panel decision but faces imminent delisting risk.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-01
Item 3.01
authID Inc. received a deficiency notice from Nasdaq on August 27, 2026, for failing to maintain the minimum bid price of $1.00 per share for 30 consecutive business days, triggering a 180-day compliance period ending February 23, 2027. The filing explicitly discloses the delisting risk under Item 3.01, noting that failure to regain compliance could result in delisting and that the company also faces a separate stockholders' equity deficiency that could preclude eligibility for a second compliance period. This is a material disclosure of delisting risk that would significantly affect investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 75%
filed 2026-09-01
EX-99.1
Universe Pharmaceuticals held its 2026 Annual General Meeting on September 30, 2026, with shareholders voting on re-election of five directors (LAI Gang, YANG Lin, PANG Jiawen, ZHENG Ding, YU Yongping), approval of a 10-for-1 share consolidation contingent on stock price falling below $1.00 for three consecutive trading days, adoption of an amended memorandum of association to reflect the consolidation, and authorization to adjourn the meeting. The proposed reverse split signals potential delisting risk mitigation efforts and is material to investors.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-09-01
The filing discloses the departure of Katharyn Field as Interim CEO, CFO, Treasurer, and Secretary, effective August 26-31, 2026. While the filing also includes the appointment of Mika Grasso as Interim CEO and Anna Skowron as CFO, the principal disclosed action centers on Field's transition and resignation from multiple executive and board roles. The filing explicitly states her departure was not due to disagreement, and she transitioned to a consulting arrangement. The departure of a sitting CEO and CFO is material to investors.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-01
EX-99.1
This news release announces significant exploration drilling results at Collective Mining's flagship Guayabales Project, specifically the discovery of a substantial northern extension to the Apollo breccia body with high-grade mineralization (38.00m @ 15.46 g/t AuEq) and a 170-meter vertical extension. The disclosure is a material operational/exploration milestone that would affect a reasonable investor's assessment of the company's resource potential and project value, but it does not fit the discrete event categories (no M&A, no earnings release, no executive changes, no impairment). This is a material exploration discovery announcement typical of junior mining companies.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 85%
filed 2026-09-01
Central Puerto's Board has authorized a share repurchase program of up to US$30 million (not exceeding 10% of share capital) to be executed over 180 days. While technically a capital allocation decision, share repurchases are classified as dividend_distribution under the taxonomy because they represent a return of capital to shareholders. The authorization specifies maximum price (US$16 per ADR on NYSE, AR$2,600 per share locally), funding source (unrestricted reserves), and execution constraints, making this a material capital deployment decision affecting shareholder value.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-01
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Des Moines. Schedule A lists multiple debt securities with trade dates in August 2026, settlement dates in September 2026, and principal amounts ranging from $10 million to $1.035 billion, representing new debt obligations. The Bank explicitly states that "consolidated obligations issuance is material to the Bank," confirming the materiality of this debt creation event.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-01
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds totaling $65 million across three separate debt securities (trade dates 08/26/2026 and 08/27/2026, with maturities ranging from 2029 to 2033). This is a classic debt issuance under Item 2.03, with Schedule A providing detailed terms including CUSIP numbers, coupon rates (4.5%-5.31%), settlement dates, and call provisions. The filing explicitly states that "consolidated obligations issuance is material to the FHLBank," confirming materiality.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-01
Item 2.03
The filing discloses the issuance of Consolidated Bonds and Consolidated Discount Notes by the Federal Home Loan Bank of Cincinnati, creating direct financial obligations. Schedule A lists six Consolidated Bonds with trade dates of 8/27/2026 and settlement dates in August–September 2026, totaling approximately $551.5 million in principal. The filing explicitly states that "Consolidated Obligations issuance is material to the FHLB," and Item 2.03 is the standard vehicle for reporting creation of direct financial obligations through debt issuance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-01
Item 2.02
Palo Alto Networks issued a press release on September 1, 2026 announcing financial results for its fiscal fourth quarter and full fiscal year ended July 31, 2026. The disclosure includes detailed quarterly and annual revenue, operating income, net income, cash flow metrics, and forward guidance for Q1 and FY2027. This is a standard earnings release disclosure under Item 2.02, with the press release furnished as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-01
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Pittsburgh. Schedule A details multiple debt issuances with trade dates in August 2026, including fixed-rate bonds ranging from $5 million to $500 million and variable-rate floaters, with maturities spanning from 2026 to 2041. This is a classic debt_issuance event under Item 2.03, and the filer explicitly notes that "consolidated obligations issuance is material to the FHLBank."
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-01
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Chicago. Schedule A details eight separate debt issuances with trade dates in late August 2026, ranging from $10 million to $65 million in principal amount, with maturities from 2031 to 2046 and coupon rates from 4.5% to 6.0%. This is a classic Item 2.03 debt issuance disclosure, and the Bank explicitly notes that "consolidated obligations issuance is material to the Bank."
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-01
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds by the Federal Home Loan Bank of Boston. Schedule A details three specific bond issuances with trade dates in August 2026, totaling $70 million in principal ($20M, $35M, and $15M), with maturity dates ranging from 2028 to 2036 and fixed coupon rates of 4.420%, 4.975%, and 4.620% respectively. This is a classic Item 2.03 debt issuance disclosure, and the Bank's joint and several liability for all FHLBank consolidated obligations makes these obligations material to investors assessing the Bank's financial position.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-01
Item 2.03
The filing discloses the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Atlanta on trade dates 8/27/2026 and 8/28/2026, totaling approximately $3.02 billion in principal amount across four separate debt securities with varying maturities (2027–2031), coupon structures (fixed and variable), and call provisions. This constitutes creation of direct financial obligations under Item 2.03, which is the core definition of debt_issuance in the taxonomy.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-01
Item 2.03
The filing discloses the Federal Home Loan Bank of Indianapolis becoming the primary obligor on consolidated obligation bonds with settlement dates in September 2026 and maturities ranging from 2029 to 2029, totaling $60 million in par value across four bond issuances. This constitutes creation of a direct financial obligation under Item 2.03, fitting the debt_issuance category as a new debt obligation with specified terms, coupons (4.500%-4.550%), and maturity dates.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-01
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds by the Federal Home Loan Bank of Dallas. Schedule A details six bond issuances with trade dates of 8/26/2026–8/28/2026, maturity dates ranging from 2028 to 2046, and aggregate par amounts of $105 million. This is a classic debt_issuance event under Item 2.03, representing new direct financial obligations of the registrant.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-09-01
Item 8.01
Chegg repaid the remaining $33.9 million of its 0% convertible senior notes at maturity on September 1, 2026, achieving a debt-free balance sheet. While this is a positive financial milestone, it represents the scheduled retirement of existing debt rather than a new debt issuance (debt_issuance), a covenant breach, or a material impairment. The event is clearly financial in nature and material to investors as it eliminates all outstanding debt and strengthens the company's financial position, but does not fit neatly into the specific financial event categories provided.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-01
Item 8.01
Emergent received a $24 million contract modification from BARDA to supply additional doses of CYFENDUS® anthrax vaccine. This is a material government procurement contract award that represents a significant operational and revenue event for the company, but does not fit neatly into the specific financial categories (debt, dividend, impairment, etc.). The event is clearly operational—a material contract/procurement milestone—making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-01
Item 5.02
Greenlight Capital Re appointed John Welch as an independent director effective September 1, 2026, and simultaneously appointed him to three board committees (Audit, Compensation, and Underwriting). The company also elected Ariel Warszawski as a director at its July 28, 2026 Annual General Meeting. Both appointments strengthen the board's governance and oversight capabilities.
View raw filing on EDGAR →